In this article
FDA Accelerated Approval for Refractory CLL and SLL
The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have undergone at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
BRUIN Clinical Trial and Patient Population
The study looked at how well it worked in BRUIN (NCT03740529), a worldwide, open-label, single-arm, multicohort trial with 108 people who had CLL or SLL and had already had at least two other treatments, including a BTK inhibitor and a BCL-2 inhibitor. Patients underwent a median of 5 previous lines of therapy, with a range from 2 to 11. Seventy-seven percent of patients stopped using the previous BTK inhibitor due to refractory or worsening illness. The drug pirtobrutinib was given orally at a dosage of 200 mg once a day and was maintained until disease progression or unacceptable toxicity occurred.
Efficacy Outcomes and Response Rates
The primary efficacy metrics were the overall response rate (ORR) and duration of response (DOR), evaluated by an independent review committee based on the 2018 iwCLL criteria. The objective response rate (ORR) was 72% with a 95% confidence interval (CI) of 63% to 80%, and the median duration of response (DOR) was 12.2 months with a 95% CI of 9.3 to 14.7. All responses were incomplete.
Common Side Effects and Safety Warnings
The most frequent side effects (≥ 20%), not including laboratory-related terms, were fatigue, bruises, cough, musculoskeletal discomfort, COVID-19, diarrhea, pneumonia, stomach pain, dyspnea, bleeding, edema, nausea, pyrexia, and headache. Grade 3 or 4 laboratory abnormalities affecting more than 10% of patients included reduced neutrophil counts, anemia, and decreased platelet counts. 32% of patients experienced severe infections, with fatal infections reported in 10% of cases. The prescribing material includes cautions and advisories for infections, bleeding, cytopenias, cardiac arrhythmias, and subsequent primary cancers.
Recommended Dosage and Administration
The suggested pirtobrutinib dosage is 200 mg taken orally once a day until disease progression or intolerable effects.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.